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Abstract—Background: Plasma amyloid -peptide (A) 40 and A42 levels are increased in persons with mutations
causing early-onset familial Alzheimer’s disease (AD). Plasma A42 levels were also used to link microsatellite genetic
markers to a putative AD genetic locus on chromosome 10 and were observed in patients with incipient sporadic AD.
Methods: The authors measured plasma A40 and A42 levels using a sandwich ELISA after the initial examination of
530 individuals participating in an epidemiologic study of aging and dementia. Participants were examined at 18-month
intervals, and plasma A40 and A42 levels were repeated in 307 subjects 3 years after baseline. Results: Compared with
individuals who never developed AD, patients with AD at baseline and those who developed AD during the follow-up had
significantly higher A42, but not A40, plasma levels. The risk of AD in the highest quartile of plasma A42 was
increased by more than twofold over that in the lowest quartile. The highest plasma A42 levels were observed in patients
with AD who died during the follow-up. Plasma A42, but not A40, levels decreased over time in patients with newly
acquired AD. Conclusions: Plasma A40 and A42 increase with age and are strongly correlated with each other. Plasma
A40 and A42 levels are elevated in some patients before and during the early stages of AD but decline thereafter. High
plasma A42 levels may also be associated with mortality in patients with AD.
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Amyloid -peptide (A) peptide deposition in the
brain and blood vessels is a distinctive manifestation
of Alzheimer’s disease (AD).1 Two peptides of 40 and
42 amino acids in length (A40 and A42) are de-
rived from the larger -amyloid precursor protein
(APP), which is expressed throughout the body. The
A peptides have also been detected in CSF, urine,
plasma, and skin.2-7 A42 is increased in the plasma
of affected and unaffected family members with mu-
tations in presenilin 1 and 2 and the APP that cause
early-onset familial AD.8 Plasma A40 and A42 lev-
els represent a heritable trait that has been used in
a linkage analysis of chromosome 10 to AD, suggest-
ing that variant forms of a gene may be associated
with elevated levels of A42.9,10 The source of A40
and A42 in plasma is unknown, however. The brain
has been considered the origin of deposited A in the
brain of patients with AD, but peripheral sources
such as blood may also be important.11
Compared with age-matched control subjects,
A40 and A42 levels are significantly increased in
the plasma of patients with Down syndrome and fur-
ther increased in the presence of dementia or the 4
variant of APOE.12 We previously reported an in-
crease in plasma A42 among individuals with incip-
ient AD in a previous study.6 Our results suggested
that plasma A42 might be a biological risk factor
for AD but was not useful as a diagnostic test. The
current study was designed to extend the risk analy-
sis of plasma A42 levels with incident AD and to
determine whether plasma A42 levels change with
disease progression, age, or other characteristics.
Methods. Study population. Plasma A40 and A42 and clini-
cal data were obtained from 530 individuals randomly selected
from 2,126 Medicare recipients, 65 years and older, residing in
northern Manhattan in New York City and participating in a
study of aging and dementia. The sampling procedures for the
parent study have been described elsewhere.13 Participants under-
went an in-person structured interview of health, a physical and
neurologic examination, and a neuropsychological battery at the
time of study entry, which was repeated at approximately 18-
month intervals. Only individuals who completed at least one
follow-up were included in the analyses. The Columbia University
Institutional Review Board reviewed and approved this project.
All individuals provided written informed consent.
Clinical assessments. Physicians completed standardized
medical and neurologic histories and examinations. With use of a
standard protocol, standing body weight to the nearest 0.1 kg with
a balance scale (Scale-Tronix, Wheaton, IL) and height without
shoes to nearest 0.5 cm were measured using a stadiometer (GNP,
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Geneva, Switzerland) to calculate body mass index (BMI 
weight/height2).
The neuropsychological test battery, previously validated for
this geographic area,14,15 was given in either Spanish or English.
The battery consisted of the orientation subtest from the modified
Mini-Mental State Examination,16 the Boston Naming Test,17 the
Controlled Word Association Test,18 category naming, the Complex
Ideational Material and Phrase Repetition Subtests of the Boston
Diagnostic Aphasia Evaluation,19 the Abstract Reasoning and
Similarities Subtests from the Wechsler Adult Intelligence Scale–
Revised,20 the nonverbal Identities and Oddities Subtest of the
Mattis Dementia Rating Scale,21 the Rosen Drawing Test,22 the
matching version and the multiple-choice version of the Benton
Visual Retention Test,23 and the Selective Reminding Test.24
After each clinical assessment, a group of physicians and neu-
ropsychologists reviewed the data and reached a consensus re-
garding the presence or absence of dementia25 using published
criteria for probable and possible AD.26 Severity of AD was rated
using the Clinical Dementia Rating Scale (CDR).27 The consensus
group was shielded from the plasma A levels.
Ethnic group. At baseline, ethnic group was documented by
self-report using the format of the 1990 US Census.28 All individ-
uals were first asked to indicate their racial group and then
whether or not they were of “Hispanic origin.”
Plasma lipids. Fasting plasma total cholesterol and triglycer-
ide levels had also been determined from plasma ascertained at
baseline using standard enzymatic techniques. High-density li-
poprotein (HDL) cholesterol was determined after precipitation of
ApoB-containing lipoproteins with phosphotungstic acid. Low-
density lipoprotein cholesterol levels were calculated using the
formula of Friedewald et al.29 This was done to examine the puta-
tive relation between alterations in cholesterol and A levels in
AD.30
APOE genotype. Genotypes were obtained by amplification of
genomic DNA with PCR subjected to CfoI restriction analysis
using APOE primers and conditions similar to those described by
Hixson and Vernier31 and modified by Maestre et al.32
Plasma A40 and A42. Plasma obtained at baseline and
follow-up was stored within 2 hours after collection at 70 °C.
A40 and A42 levels were measured using a combination of
monoclonal antibody 6E10 (specific to an epitope present on 1 to
16 amino acid residues of A) and rabbit antibodies specific for
A40 (R162) and A42 (R165) in a double-antibody sandwich
ELISA.33,34 The detection limit for this assay was 5 pg/mL for A40
and 10 pg/mL for A42. Previously, we had established that the
test–retest reliability of the measurement of plasma A40 and
A42 was excellent (Cronbach’s  coefficient  0.91).6
Data analysis. Continuous measures were compared across
groups using Student’s t-test, and categorical variables were com-
pared using the 2 test. We subtracted the value of the plasma A
levels at baseline from that acquired 3 years later to estimate the
change in levels over time. The change was compared using anal-
ysis of variance. Correlations between variables were completed
using Pearson’s correlation coefficient. Log transformation was
used for continuous variables that appeared skewed. Univariate
regression models were used to determine the relation between
AD and plasma A levels, and multivariate regression models
were used to adjust for potential confounders. Finally, we used
Cox regression to examine the rate ratio for AD associated with
plasma A42 levels divided into quartiles, in which the lowest
quartile was used as the reference. For these analyses, we used
duration of follow-up from the baseline measurement of plasma
A levels as the time-to-event variable. In subsequent analyses,
we adjusted for age, education, APOE genotype, and BMI. All
analyses were conducted using SPSS for Windows (version 10.1.3;
Chicago, IL).
Results. At the baseline assessment, there were 79
(14.9%) patients with clinically diagnosed AD (CDR  1.0)
among the 530 individuals in the study. The remaining
451 individuals were free of dementia (400 were CDR  0
and 51 CDR  0.5). Over the subsequent 5 years, 65
(16.3%) of the 400 without dementia and 21 (41.2%) of
those with mild impairment (CDR  0.5) developed AD
(CDR  1).
Compared with those who remained healthy, there were
more African Americans and Hispanics than whites and
more women than men with AD at baseline (table 1). Pa-
tients with AD were also older, less well educated, and
more likely to have an APOE-4 allele than those without
dementia. Over the follow-up period, more African Ameri-
cans and Hispanics than whites and more women than
men developed AD (see table 1). Individuals who developed
AD were more likely to be older, less well educated, and
more likely to have an APOE-4 allele than those who
remained free of dementia. BMI was lower among the pa-
tients with AD at baseline than among newly diagnosed
patients with AD or control subjects (see table 1).
Plasma A40 and A42 levels were correlated (r  0.22,
p  0.001), and both increased with age (A40 r  0.23,
p  0.001; A42 r  0.15, p  0.001). A40, but not A42,
levels were inversely related to serum cholesterol and HDL
levels (r  0.12, p  0.005, for both). A42, but not A40,
level was inversely related to BMI (r  0.1, p  0.05).
Neither A40 nor A42 levels differed by the presence or
absence of an APOE-4 allele.
The initial A40 and A42 levels differed significantly
in those individuals with AD at baseline compared with
those without dementia (see table 1). More importantly,
A40 and A42 levels were significantly higher in those
who subsequently developed AD over the follow-up period
(see table 1). The baseline A40 levels, but not the A42
levels, differed between those with CDR  0 and those
with CDR  0.5 (A40 131.5 [52.8; SD] vs 152.6 [94.8]
pg/mL, p  0.05; and A42 61.3 [40.8] vs 69.5 [31.9] pg/
mL, p  0.2). However, regardless of the initial CDR, those
who subsequently developed AD had higher baseline A42
than those who never developed AD (A42 CDR 0  77.4
[66.5], CDR 0.5  73.8 [31.9] vs controls 58.8 [32.9]; F 
14.1, p  0.0001).
Because the distributions of A40 and A42 levels were
skewed, the comparison was repeated using log transfor-
mations of A40 and A42 levels, and all of the associa-
tions with newly acquired AD described above remained
significant. However, with multivariate analysis of covari-
ance adjusting for age, BMI, and A40 level, only A42
levels remained significantly different when comparing
those who never developed AD with those who developed
AD over the follow-up period. In contrast, there were no
significant differences in the A40 level across the groups
in the adjusted analysis. We also found no differences in
the plasma A40 and A42 levels by disease severity using
either the first or the last CDR rating. However, only two
individuals had CDR ratings that exceeded 2, which re-
flects the fact that most patients had only mild disease.
Compared with the lowest quartile of plasma A42 level
at baseline, the unadjusted rate ratio for AD was signifi-
cantly increased for each successive quartile after the sec-
ond quartile (table 2). This association did not change in a
multivariate Cox regression model that included A40
level, age, BMI, education, and APOE-4. The figure shows
the cumulative proportion of affected individuals within
each quartile of plasma A42. Only the upper two quar-
tiles differed significantly from the lowest quartile, though
the risk did increase for each quartile.
The baseline A42 plasma level was also consistently
and significantly higher among those individuals who de-
veloped AD at any time point during the follow-up than
among those who never developed AD after 5 years of
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follow-up (mean A42 levels for controls over the entire
period 58.8 pg/mL, AD after 2 years of follow-up 77.1 pg/
mL, AD after 4.1 years of follow-up 74.5 pg/mL; F  6.04,
p  0.003). Thus, the average plasma A42 levels were
consistently elevated among those who subsequently de-
veloped AD compared with those who remained
dementia-free.
We were able to obtain repeat blood samples in only 307
(58%) of the 530 individuals. This was due in part to mor-
tality among 157 (29.6%) of the participants. Nonetheless,
the correlation between the initial and subsequent plasma
A40 and A42 levels was high (0.979 and 0.963, respec-
tively). The change in overall mean A40 levels differed
slightly, but significantly, increasing over time (2.44 pg/
mL; 95% CI 0.9 to 3.9). There was no significant change in
A42 level over time (0.009 pg/mL; 95% CI 0.83 to
0.82), but in comparison there were significant differences
in plasma A42 levels among the different groups over
time. Among controls that remained dementia-free, the
average difference over the 3 years was 0.25 pg/mL, for
prevalent AD the difference was 0.75 pg/mL, whereas the
difference among patients with incident AD was 3.02
pg/mL (F  4.2, p  0.02). This difference was significant.
Thus, the average decline in plasma A42 levels was 1.006
pg/mL/year in patients with newly acquired AD.
We found that baseline plasma A40 and A42 levels
were significantly higher among those who died before the
final assessment (table 3). Specifically, those individuals
with AD who subsequently died had higher baseline A42
levels than those individuals without AD, those with AD at
Table 1 Baseline demographics by final diagnoses
Demographics, n  530 AD at baseline AD at follow-up Nondemented elderly*
No. (%) 79 (14.9) 86 (16.2) 365 (68.9)
Mean (SD) age,† 83.2 (7.9) 79.3 (6.6) 75.5 (5.9)
Mean (SD) education,† 6.4 (4.2) 6.8 (4.5) 9.0 (4.6)
Gender,‡ women % 86.1 79.1 66.6
African American, % 15.7 16.8 67.5
Caribbean Hispanic, % 17.5 19.7 62.8
White, % 6.6 7.6 85.8
APOE-ε4 present,§ % 39.2 32.1 26.7
BMI (SD)§ 25.7 (4.9) 27.4 (6.2) 27.5 (5.8)
Mean (SD) cholesterol, mg/dL 198.1 (42.3) 196.0 (41.4) 201.2 (40.8)
Mean (SD) A40,§ pg/mL 153.6 (46.7) 136.2 (46.7) 133.3 (61.9)
Mean (SD) A42,†§¶ pg/mL 68.7 (24.2) 76.5 (59.8) 58.8 (32.9)
Mean (SD) A42/A40*§ 0.49 (0.23) 0.61 (0.53) 0.48 (0.3)
Note that for ethnic groups, the percentages reflect within-group proportions. African Americans do not include Hispanics. Hispanics
are exclusively from the Caribbean Islands and Central and South America. Whites are of Eurasian ancestry and not Hispanic.




Linear trend, P  0.05.
¶Linear trend, P  0.001.
AD  Alzheimer’s disease; BMI  body mass index; λA  amyloid -peptide.
Table 2 Rate ratio of AD by plasma A42 levels as quartiles
Quartiles of A42, pg/mL No. at risk AD, no. (%) RR (95% CI)* RR (95% CI)†
36.97 124 19 (15.3) 1.0 ref. 1.0 ref.
36.97–60.2 116 19 (16.4) 1.3 (0.7–2.4) 1.1 (0.6–2.1)
60.2–84.15 102 21 (20.6) 1.9 (1.1–3.6)‡ 1.9 (1.0–3.7)‡
84.15 109 27 (24.8) 2.4 (1.3–4.3)§ 2.5 (1.3–4.8)§
Note that prevalent AD is omitted from this analysis of disease risk by baseline A42 levels. The time-to-event was duration of
follow-up from the baseline evaluation. All subjects were dementia-free at that time.
*Unadjusted.
†Adjusted for age, education, A40 level, APOE genotype, and body mass index.
‡P  0.05.
§P  0.006.
AD  Alzheimer’s disease; A  amyloid -peptide; RR  rate ratio.
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baseline, and patients who developed AD and survived.
The analysis was repeated using multivariate analysis of
covariance adjusting for age, BMI, and baseline plasma
A40 level, and the difference remained significant.
Plasma A40 levels did not differ significantly in those
who survived with or without AD and those who did not in
the multivariate analysis. The unadjusted analysis was
repeated using log transformation of the values for plasma
A40 or the A42 levels, and the differences remained
statistically significant.
Discussion. Compared with elderly without AD,
patients with AD and individuals who developed AD
over the follow-up period had higher plasma A40
and A42 levels at the beginning of the study.
Plasma A40 and A42 levels were also higher in
patients with AD at baseline compared with controls,
though the differences were smaller. With use of the
lowest quartile as the reference group, individuals in
the upper two quartiles of plasma A42 were at
twice the risk of developing AD over the follow-up
period. As a group, plasma levels of A40 and A42
drawn 3 years apart did not change significantly, but
there was a significant decline in plasma A42 levels
in patients with newly acquired AD compared with
those with prevalent AD or with controls. Over the
study period, both plasma A40 and A42 levels
were higher among those participants who died dur-
ing the follow-up period than among those who sur-
vived. However, the multivariate analysis showed
that baseline A42 levels were higher in patients
with recent onset of AD who died compared with
those who survived with or without AD. This work
extends our previous study, pointing out that differ-
ences in plasma level are related to age, BMI, and
duration of time after the diagnosis. It also shows
that the risk of AD may remain increased for those
individuals with elevated plasma 42 over nearly 10
years.
Mutations in the genes that cause early-onset, fa-
milial forms of AD increase the extracellular concen-
tration of A42, which may augment A deposition
in the form of plaques in the brain.35 This has led to
the hypothesis that cerebral A deposition is an es-
sential early event in the pathogenesis of all forms of
AD. Support for this hypothesis has come from the
observation that plasma A40 and A42 levels were
found to be higher in family members with muta-
tions in presenilin 1 and the APP than among family
members without the mutation.8 We previously re-
ported that plasma A42, but not A40, levels were
increased among patients with incipient AD regard-
less of their APOE genotype in a small study from
this same community.6 Though patients with Down
syndrome have higher plasma A40 and A42 levels
due to the trisomy involving the region containing
the APP,36 even higher levels are found among pa-
Figure. Risk of Alzheimer’s disease (AD) by quartiles of
amyloid -peptide (A42) plasma levels at baseline. This
graph depicts the cumulative proportion of individuals
developing AD over the entire period of follow-up by the
plasma A42 level at the baseline or initial visit. Quartiles
of plasma A42 are identified as follows: filled circles 
84.15 pg/mL; triangles  84.15 to 60.2 pg/mL; asterisks 
60.2 to 36.97 pg/mL; open circles  36.97 pg/mL.
Table 3 Relation of plasma A40 and A42 levels, diagnosis, and vital status at last follow-up
Group Status* No. Age† A40, pg/mL A42, pg/mL
AD baseline Alive 32 81.3 (7.5) 143.9 (40.6) 66.3 (23.6)
Dead 45 84.6 (7.9) 160.4 (49.9) 70.3 (24.7)
Nondemented elderly Alive 277 74.8 (5.6) 122.1 (39.7)‡ 57.6 (33.7)
Dead 88 77.4 (6.6) 168.3 (96.9) 62.8 (30.1)
AD follow-up Alive 63 78.2 (5.6) 128.9 (45.8) 67.6 (49.8)§
Dead 23 82.4 (8.1) 155.9 (45.0) 101.2 (77.1)
Comparisons are between participants who were alive or dead at the final assessment. Log-transformed values also differed signifi-
cantly. Values in parentheses are SD.
*Status refers to the vital status at final assessment.
†Both nondemented elderly and patients with AD who died were significantly older than those surviving.
‡P  0.001, comparing nondemented elderly follow-up alive vs dead.
§P  0.01, comparing AD follow-up alive vs dead.
A  amyloid -peptide; AD  Alzheimer’s disease.
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tients who became demented.12,37 It is not clear
whether the APOE genotype influences plasma A40
and A42, because there are opposing reports.12,37
A40 and A42 levels in plasma represent a herita-
ble trait9 that has been used as a phenotype in a
genetic linkage analysis10 that showed genetic link-
age to markers on chromosome 10.
Do plasma A42 levels represent a potential bio-
logical risk factor for AD? Our study has indicated
that the answer to this question is complex. First,
plasma A40 and A42 levels show some degree of
overlap between elderly individuals who eventually
develop AD and those who remained healthy, as
would be expected with any risk factor. Second, we
demonstrated that the measurement of plasma A42
levels would need to be done at a point well before
the onset of disease and thus could be used in the
detection of individuals at higher-than-average risk.
Careful inspection of the figure suggests that differ-
ences in frequency of AD by plasma A42 levels
emerge only after 2 to 3 years of follow-up. There-
fore, a cross-sectional comparison of patients with
established diagnoses of AD and control subjects
would be unlikely to show a difference in the mean
levels of either peptide. Third, the validity of plasma
A42 levels as a risk factor will be difficult to estab-
lish without more extensive longitudinal data be-
cause the highest levels were observed among
individuals in the earliest stages of disease when the
specificity of diagnosis is low. Therefore, high-risk
individuals will need follow-up to a point at which
the diagnostic specificity is greater. Although we ob-
served little difference in the levels over a 3-year
period, it may be necessary to complete repeated
testing over a longer interval to examine changes in
plasma levels with regard to disease course. Fourth,
the highest A40 and A42 were found in those pa-
tients who died during the follow-up period, again
implying that longitudinal, not cross-sectional, stud-
ies will be required to determine their usefulness in
assessing disease risk. An alternative explanation is
that the association with mortality implicates
plasma A40 and A42 levels as indicators of
prognosis.
We believe that neither plasma A40 nor A42
levels will be useful in the diagnosis of AD. Our
limited results with repeated samples indicate that
the plasma levels of A42 begin to decrease soon
after the diagnosis of AD has been established,
which has been observed by others.38 Exactly when
plasma levels begin to decrease is uncertain. In con-
trast, CSF concentrations of A42 have been used
successfully when combined with other biochemical
markers such as 	 in the diagnosis of probable
AD.39,40 A42 in the CSF is lower in patients with the
disease than in controls. CSF concentrations of A42
are increased early in the disease and decrease over
time.41 Previous studies examining the role of
plasma A40 and A42 levels have shown little or no
value in the diagnosis of AD.5,42
We found an inverse relation between A40 levels
and cholesterol and HDL in plasma. There may well
be a relationship between A deposition in brain and
cholesterol, but it has not been observed in plas-
ma.43,44 We could not identify an association between
increased plasma A and elevated serum cholester-
ol.45 The studies of families with early-onset AD
caused by mutations and the recent linkage of fami-
lies with late-onset disease to chromosome 10 impli-
cate exceptionally high plasma A42 levels as part of
the phenotype of a form of familial AD. Thus, an
alternative possibility is that plasma A42 may be
increased only in a subset of individuals who develop
AD. If the elevation in A42 is a phenotypic marker
in some, but not all, patients, then the search for the
genes associated with higher levels will be extremely
important because new metabolic pathways may be
revealed. The persistence of the elevation in the pa-
tients studied here, the sparse number of individuals
with elevated levels, and their death over the
follow-up would suggest a moderately aggressive
form of the disease that can be either genetic or
environmental.
Aside from studies of early-onset familial AD,46,47
there have been no reports suggesting that elevated
levels of circulating plasma A40 or A42 are associ-
ated with mortality. It is intriguing to speculate that
in some individuals with AD, higher levels of A40
and A42 may reflect a more advanced stage of dis-
ease or a more aggressive form of AD. The only ani-
mal model that has been studied is the senescence-
accelerated mouse, which has a short life span and
shows early signs of aging.48 However, the amyloid
deposition is systemic, affecting numerous systems
in the body.
The source of A40 and A42 in plasma is un-
known. A is derived from proteolytic cleavage of the
APP.1 APP is produced by a variety of cell types in
the brain and elsewhere, but the origins of A brain
deposits in AD and deposits in the cerebral vessels
are uncertain. Amyloid deposits in cerebral vessels
may be derived from circulating A.49 Some have
suggested that the source of parenchymal cerebral
amyloid deposits may originate in the periphery.50
Platelets contain high levels of membrane-associated
and soluble forms of APP, which, when cleaved, can
release A.51-53 Platelets may also be the source of A
detected in whole blood54 because A, like APP, is
also released upon platelet activation.52,55 A and
APP formation and subsequent release from human
platelets may be regulated by different multiple sig-
nal transduction mechanisms.11 Knowledge of these
mechanisms could provide a key to the pathogenesis
of AD.
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